Belinsky et al. used sputum and serum to identify methylation targets for NSCLC and found that p16, DAPK, PAX5b, and GATA5 were potential biomarkers for NSCLC [71]. This evidence concerns the gene GATA5 and non-small cell lung carcinoma.